Annual report pursuant to Section 13 and 15(d)

SCHEDULE OF SEGMENT INFORMATION (Details)

v3.24.4
SCHEDULE OF SEGMENT INFORMATION (Details) - USD ($)
$ in Thousands
 12 Months Ended
Oct. 31, 2024
Oct. 31, 2023
Segment Reporting Information [Line Items]    
Net income (loss) $ (12,698) $ (9,930)
Total operating costs and expenses 13,831 11,221
Less non-cash stock-based compensation (4,782) (4,735)
Operating costs and expenses excluding non-cash share based compensation 9,049 6,486
Total assets 21,591 25,522
Cancer Vaccines [Member]    
Segment Reporting Information [Line Items]    
Net income (loss) (7,388) (5,111)
Operating costs and expenses excluding non-cash share based compensation 5,235 3,265
Total assets 12,917 17,215
CAR-T Therapeutics [Member]    
Segment Reporting Information [Line Items]    
Net income (loss) (5,256) (3,879)
Operating costs and expenses excluding non-cash share based compensation 3,766 2,467
Total assets 8,535 7,523
Other [Member]    
Segment Reporting Information [Line Items]    
Net income (loss) (54) (940)
Operating costs and expenses excluding non-cash share based compensation 48 754
Total assets $ 139 $ 784